Related Experiment Video

Updated: Oct 15, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.6K

Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy

Rory M Shallis1, Darko Pucar2, Sudhir Perincheri3

  • 1Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, 333 Cedar Street, PO Box 208028, New Haven, CT, 06520-8028, USA.

Annals of Hematology
|October 23, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.4K
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.1K

Related Experiment Videos

Last Updated: Oct 15, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.6K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.4K
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K

Articles linked to this work by shared authors, journal, and citation graph.

Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.

Haematologica·2026

Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.

Leukemia·2026

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

American journal of hematology·2026

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

Blood advances·2026

The burden of acute myeloid leukemia: an integrated review of clinical, economic, and patient-centered evidence.

Expert review of anticancer therapy·2026

Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy.

Leukemia & lymphoma·2026

Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia.

Annals of hematology·2026

Change in COVID-19 outcomes in lymphoma patients across pandemic waves: results of the COVID-19-lymphoma registry of the Bavarian Cancer Research Center (BZKF) 2020-2022.

Annals of hematology·2026

Diagnosis and treatment of familial hemophagocytic lymphohistiocytosis with isolated central nervous system involvement: A case report.

Annals of hematology·2026

Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries.

Annals of hematology·2026

Deep learning differentiates myeloproliferative neoplasms and predicts JAK2 and CALR mutations from bone marrow smears.

Annals of hematology·2026

Liver iron concentration and renal dysfunction in β-thalassemia: a case series and exploratory clinical observations.

Annals of hematology·2026

Progress in Synthesis and Pharmacology of Telmisartan.

Chemistry & biodiversity·2026

Functional psychosurgery in psychiatry: indications and preoperative evaluation. A narrative review.

Frontiers in psychiatry·2026

Development of humanized mouse models for the preclinical evaluation of NK cell-based therapies.

Frontiers in immunology·2026

Focused Ultrasound is Poised to Take Non-Viral Gene Therapies to the Blood-Brain Barrier - and Beyond.

Cell biomaterials·2026

pAc/Emm55 increases anti-melanoma immunity via TLR2 signaling in dendritic cells and improves checkpoint blockade efficacy.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us